Rapid, non-invasive, cost effective.
Like the blood, the breath has its own biomarkers that can be used to indicate signs of disease.
We are leading in the discovery of these biomarkers, and bringing breath diagnostics into regular clinical practice.
We are starting with lung cancer and breast cancer, but this technology has applicability across a broad range of areas.
60
participants in
initial trials
98%
accuracy in detecting
grade 2 & 3 breast cancer
10
minutes sampling time
3
devices in active R&D
The team behind Respiro Dynamics
Theo Issitt, PhD
A breath analysis expert with experience in volatile biomarker research and development of breath collection platforms.
Alison Quinn
Commercial leader with experience in healthcare product development, go-to-market strategy, and partnerships.
With support from
Support non-invasive solutions for earlier detection, diagnoses, and precision medicine.
Created by Respiro Dynamics.
Contact us at info@respirodynamics.com
